Bifido
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Bifido makes probiotic supplements, live beneficial bacteria in powder and finished-product form, designed to support gut health for consumers.
It supplies these products under its own brand, BIFIDO LAB, and also provides ODM (original design manufacturing) services, developing and producing probiotic goods for other companies under their own labels. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business rests on proprietary bacterial strains originally isolated from Korean infants, and it is also developing microbiome-based therapeutic drugs as a separate pipeline alongside its consumer health business.
Summary is AI-generated and may contain errors · figures from DART filings
Bifido holds US FDA new dietary ingredient and safety certifications for its proprietary strains, and one strain has been registered in the United States Pharmacopeia.
Bifido in five facts
What does Bifido do?
Bifido makes probiotic supplements, live beneficial bacteria in powder and finished-product form, designed to support gut health for consumers.
Where is Bifido listed and in which sector?
Bifido (Korean name: 비피도) trades under KRX code 238200 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Food & Beverage.
How large is Bifido?
Its market capitalisation was US$16.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Bifido's latest annual revenue and operating profit?
For fiscal year 2025, Bifido reported revenue of US$14.9M, operating profit of US$1.1M and a net loss of US$145.5K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 59.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Completion report on merger, etc. (asset transfer)
Bifido Co., Ltd. completed, on August 14, 2026, the transfer of land and a building at 1006-12 Daechi-dong, Gangnam-gu, Seoul to Kim WJ Co., Ltd. for US$17.9M, under an asset-transfer agreement originally disclosed May 19, 2026.
M&A · Aug 14 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Bifido reported consolidated results for FY2025: revenue of US$13.6M (+59.3% year on year), operating profit of US$973K (from a loss a year earlier) and a net loss of US$134K.
Earnings · Feb 24